In8Bio (INAB) Non-Current Assets (2020 - 2026)
In8Bio (INAB) posted Non-Current Assets of $3.6 million for Q1 2026, down 18.15% sequentially from $4.4 million in Q4 2025, and down 49.57% YoY from $7.1 million in Q1 2025.
In8Bio (INAB) Non-Current Assets (2020 - 2026) Analysis & Trends
In8Bio has reported Non-Current Assets for 7 years, with the latest figure at $3.6 million in Q1 2026.
- Quarterly Non-Current Assets fell 49.57% year-over-year to $3.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.6 million (down 49.57% YoY) and the FY2025 annual result came in at $4.4 million, down 47.38% from the prior year.
- Non-Current Assets eased to $3.6 million in Q1 2026 per INAB's latest filing, from $4.4 million in the prior quarter.
- Over five years, Non-Current Assets peaked at $10.8 million in Q4 2022 and troughed at $3.3 million in Q1 2022.
- A 5-year average of $7.5 million and a median of $8.5 million in 2022 frame the typical range for Non-Current Assets.
- The sharpest annual moves came in 2022 and 2026: Non-Current Assets jumped 233.18% in 2022, then sank 49.57% in 2026.
- Over 5 years, Non-Current Assets stood at $10.8 million in 2022, then fell by 15.93% to $9.1 million in 2023, then slipped by 7.9% to $8.4 million in 2024, then slumped by 47.38% to $4.4 million in 2025, then declined by 18.15% to $3.6 million in 2026.
- According to Business Quant data, Non-Current Assets over the past three periods registered $3.6 million, $4.4 million, and $5.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.84 Bn | 131.99 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 86.48 Bn | 78.49 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 65.47 Bn | 60.29 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 60.15 Bn | 55.01 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 42.22 Bn | 37.12 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 31.67 Bn | 28.36 Bn | 992.69 Mn | 938.60 Mn |
| 7 | BioNTech SE | 28.54 Bn | 10.14 Bn | 668.28 Mn | 6.80 Bn |
| 8 | Insmed | 27.58 Bn | 26.42 Bn | 358.27 Mn | 468.65 Mn |
| 9 | Royalty Pharma | 27.22 Bn | 26.38 Bn | - | 18.06 Bn |
| 10 | In8Bio | 23.75 Mn | 23.75 Mn | - | 3.25 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.25 Mn |
| Mar 31, 2026 | 3.60 Mn |
| Dec 31, 2025 | 4.40 Mn |
| Sep 30, 2025 | 5.00 Mn |
| Jun 30, 2025 | 5.63 Mn |
| Mar 31, 2025 | 7.14 Mn |
| Dec 31, 2024 | 8.37 Mn |
| Sep 30, 2024 | 9.26 Mn |
| Jun 30, 2024 | 9.81 Mn |
| Dec 31, 2023 | 9.08 Mn |
| Sep 30, 2023 | 9.66 Mn |
| Jun 30, 2023 | 10.25 Mn |
| Mar 31, 2023 | 10.28 Mn |
| Dec 31, 2022 | 10.81 Mn |
| Sep 30, 2022 | 8.73 Mn |
| Jun 30, 2022 | 3.99 Mn |
| Mar 31, 2022 | 3.26 Mn |
| Dec 31, 2021 | 3.24 Mn |
| Sep 30, 2021 | 3.26 Mn |
| Jun 30, 2021 | 5.40 Mn |